Paper published in a journal (Scientific congresses and symposiums)
A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer
Kaufman, P.A.; Norris Cotton Cancer Center at Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
Freyer, G.; Centre Hospitalier Lyon Sud, Oncologie médicale, Pierre-Benite Cedex, France
Kemeny, M.; Queens Cancer Center, Queens, NY, USA
Gonçalves, A.; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Stopeck, A.; Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
Vrindavanam, N.; Department of Clinical Research, Signal Point Clinical Research Center (LLC), Middletown, OH, USA
Dalenc, F.; Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
Nanayakkara, N.; Quintiles, San Diego, CA, USA
Wu, B.; Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, CA, USA
Pickett, C.A.; Department of Clinical Development, Amgen Inc., Thousand Oaks, CA, USA
Wildiers, H.; University Hospitals Leuven, Leuven, Belgium
Language :
English
Title :
A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer
Publication date :
May 2015
Event name :
San Antonio Breast Cancer Symposium
Event organizer :
SABCS
Event place :
San Antonio, United States
Event date :
December 9-13, 2014
Audience :
International
Journal title :
Cancer Research
ISSN :
0008-5472
eISSN :
1538-7445
Publisher :
American Association for Cancer Research, Inc. (AACR), Baltimore, United States - Maryland
